-
Product Insights
New![]()
Net Present Value Model: Eisai Co Ltd’s Irsenontrine maleate
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eisai Co Ltd’s H-3B6545
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eisai Co Ltd’s E-2814
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eisai Co Ltd’s Farletuzumab ecteribulin
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Company Profile
![]()
Eisai Inc – Company Profile
Eisai Inc (Eisai America), a subsidiary of Eisai Co Ltd, is a healthcare company that discovers, develops, and markets pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux, Akynzeo for nausea and vomiting during the course of cancer chemotherapy, Aloxi anti-nausea medication injection, Banzel for adjunctive treatment, Dayvigo for the insomnia, and Panretin for the treatment of skin lesions in AIDS-related Kaposi's sarcoma. The company’s research and development activities focus on therapeutic areas such...
Add to Basket -
Company Profile
![]()
Eisai Co Ltd – Company Profile
Eisai Co Ltd (Eisai) is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor, Aricept, an anti-Alzheimer agent, perampanel, Halaven, an anti-cancer agent, Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK,...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: Arvinas Inc’s ARV-471
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: 89bio Inc’s Pegozafermin
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SCT-1000 in Anal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SCT-1000 in Anal Cancer Drug Details: SCT-1000 is under development for the prevention of human...
-
Product Insights
NewHypocobalaminemia (Vitamin B12) Deficiency Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hypocobalaminemia (Vitamin B12) Deficiency Clinical Trials Market Report Overview The Hypocobalaminemia (Vitamin B12) Deficiency clinical trial market research report provides an overview of the Hypocobalaminemia (Vitamin B12) Deficiency clinical trials scenario. This report provides top-line data relating to the clinical trials on Hypocobalaminemia Deficiency and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,...
-
Product Insights
NewReflux Esophagitis (Gastroesophageal Reflux Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Reflux Esophagitis (Gastroesophageal Reflux Disease) Clinical Trials Market Report Overview The Reflux Esophagitis (Gastroesophageal Reflux Disease) clinical trial market research report provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) clinical trials scenario. This report provides top-line data relating to the clinical trials on Reflux Esophagitis and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FHD-286 in Refractory Acute Myeloid Leukemia Drug Details: FHD-286 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-2814 in Dementia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. E-2814 in Dementia Drug Details: E-2814 is under development for the treatment of Alzheimer's disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – THN-391 in Alzheimer’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. THN-391 in Alzheimer's Disease Drug Details: THN-391 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-2025 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.E-2025 in Alzheimer's DiseaseDrug Details:Biologic is under development for the treatment of Alzheimer's disease. The therapeutic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ta-1505 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ta-1505 in Alzheimer's Disease Drug Details:Ta-1505 is under development for the treatment of Alzheimer’s disease (AD)....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-2814 in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. E-2814 in Alzheimer's Disease Drug Details: E-2814 is under development for the treatment of Alzheimer's...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LX-2006 in Cardiomyopathy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LX-2006 in Cardiomyopathy Drug Details:LX-2006 is under development for the treatment of cardiomyopathy associated with Friedreich’s...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Irsenontrine Maleate in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Irsenontrine Maleate in Parkinson's Disease Drug Details:E-2027 is under development for the treatment of dementia with...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MHU-650 in Retinal Vein Occlusion
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MHU-650 in Retinal Vein Occlusion Drug Details:MHU-650 is under development for the treatment of macular edema,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.